Global Capecitabine Market Growth Analysis 2024, Forecast To 2033
8 Mar, 2024
The capecitabine market (6) has demonstrated strong growth, increasing from $2.06 billion in 2023 to $2.25 billion in 2024, with a CAGR of 9.4%. This growth is attributed to advancements in chemotherapy, the convenience of oral administration, and regulatory approvals. Future growth is projected, with the market expected to reach $3.14 billion by 2028, growing at a CAGR of 8.7%. Factors such as expanded indications, research in combination therapies, and healthcare infrastructure development contribute to this growth. Key trends include targeted therapy combinations, expanded use in adjuvant settings, biomarker-driven treatment, enhanced pharmacogenomics, and telehealth monitoring.
Global Capecitabine Market Key Driver
The increasing incidence of cancer is expected to propel the growth of the capecitabine market. Capecitabine is used in cancer treatment, particularly for inhibiting DNA synthesis and slowing tumor tissue growth. The American Cancer Society reported an increase in cancer cases and deaths in the United States, with 1.9 million new cases and 608,570 deaths in 2021. Therefore, the rising incidence of cancer is driving the growth of the capecitabine market.
Get A Free Sample Of The Global Capecitabine Market ReportGlobal Capecitabine Market Segments
The capecitabine market covered in this report is segmented –
1) Drug Type:Branded, Generic
2) Drug Formulation:Tablet, Capsules
3) Distribution Channel:Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) Application:Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Other Applications
5) End-Users:Hospitals, Homecare, Specialty Centers, Other End-Users
By Geography: The countries covered in the capecitabine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the capecitabine market in 2023. The regions covered in the capecitabine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Capecitabine Industry Players
Pfizer Inc.; Merck & Co. Inc.; Bayer AG; Novartis AG; Sanofi S.A.; Sensus Healthcare Inc.; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Inc.; Genentech Inc.; Aurobindo Pharma Limited; Dr Reddy Laboratories Ltd.; Sigma-Aldrich Corp; Cipla Inc.; Hikma Pharmaceuticals plc; Lupin Limited; Alkem Laboratories Limited; Ranbaxy Laboratories Ltd.; Glenmark Pharmaceuticals Ltd.; Accord Healthcare Ltd.; Zentiva N.V.; Reliance Life Sciences Pvt Ltd.; Avita Medical Limited; Mylan Inc.; Sandoz Inc.
Get The Full Global Capecitabine Market Report
Capecitabine Market Overview
Capecitabine is a chemotherapeutic drug that inhibits DNA synthesis and decreases tumor tissue development by enzymatically transforming into the antimetabolite fluorouracil in the tumor. It is taken through the oral route of administration to treat metastatic breast and colorectal cancers.